Background
==========

We are interested in the following setting occurring in the field of meta-analysis of diagnostic studies (Hasselblad and Hedges \[[@B1]\]; Sutton *et al.*\[[@B2]\]; Deeks \[[@B3]\]; Schulze *et al.*\[[@B4]\]): a variety of diagnostic studies are available providing estimates of the diagnostic measures of specificity *q*=*P*(*T*=0\|*D*=0) as ${\hat{q}}_{i} = x_{i}/n_{i}$ and of sensitivity *p*=*P*(*T*=1\|*D*=1) as ${\hat{p}}_{i} = y_{i}/m_{i}$, where *D*=1 and *D*=0 denote presence or absence of disease, respectively, and *T*=1 or *T*=0 denote positivity or negativity of the diagnostic test, respectively, *x*~*i*~ are the number of observed true-negatives out of *n*~*i*~ healthy individuals, and *y*~*i*~ are the number of observed true-positives out of *m*~*i*~ diseased individuals, for *i*=1,...,*k*, *k* being the number of studies. For more details on the statistical modelling of the diagnostic data from a single study, see Pepe \[[@B5],[@B6]\]. For a more detailed introduction to meta--analysis of diagnostic studies, see Holling *et al.*\[[@B7]\]. In the following, we will look at several examples -- mainly from medicine and psychology -- for this special meta-analytic situation. In principle, however, applications could occur in all areas in which meta-analytic data is encountered; Swets \[[@B8]\] considers mainly psychological applications, but also mentions cases from engineering (quality control), manufacturing (failing parts in planes), metereology (correctness of weather predictions), information science (correctness of information retrieval), or criminology (correctness of lie detection test). We illustrate the special meta-analytic situation mentioned above with a meta-analysis on a diagnostic test on heart failure (see also Holling *et al.*\[[@B7]\]).

*Example 1: Meta-Analysis of diagnostic accuracy of Brain Natriuretic Peptides (BNP) for heart failure.* Doust *et al.*\[[@B9]\] provide a meta-analysis on the diagnostic accuracy of the brain natriuretic peptides (BNP) procedure as a diagnostic test for heart failure. According to the authors, diagnosis of heart failure is difficult, with both overdiagnosis and underdiagnosis occurring. The meta-analysis considers a range of diagnostic studies that use different reference standards (where a reference standard defines the presence or absence of disease). Here we only consider the eight studies (see Table [1](#T1){ref-type="table"}) using the left ventricular ejection fraction of 40% or less as reference standard.

###### 

Meta-analysis of of diagnostic accuracy of brain natriuretic peptides (BNP) for heart failure using the left ventricular ejection fraction of 40% or less as reference standard

                            **Diseased**                        **Healthy**                                                                                        
  ------------------ -------------------------- ------------------------------------------- -------------------------- ------------------------------------------- -----------------------------------
  **Study*i***        ***y***~***i***~**(TP)**   ***m***~***i***~**−*y***~***i***~**(FN)**   ***x***~***i***~**(TN)**   ***n***~***i***~**−*x***~***i***~**(FP)**   ***n***~***i***~**+*m***~***i***~
  Bettencourt 2000               29                                  7                                  46                                 19                                      101
  Choy 1994                      34                                  6                                  22                                 13                                      75
  Valli 2001                     49                                  9                                  78                                 17                                      153
  Vasan 2002a                    4                                   6                                 1612                                85                                     1707
  Vasan 2002b                    20                                 40                                 1339                                71                                     1470
  Hutcheon 2002                  29                                  2                                 102                                 166                                     299
  Landray 2000                   26                                 14                                  75                                 11                                      126
  Smith 2000                     11                                  1                                  93                                 50                                      155

*The cut--off value problem.* A separate meta--analysis of sensitivity and specificity using the meta--analytic tools for independent binomial samples is problematic when the underlying diagnostic test utilizes a continuous or ordered categorical scale and different cut--off values have been used in different diagnostic studies. A simple variation of the cut--off value from study to study might lead to quite different values of sensitivity and specificity without any actual change in the diagnostic accuracy of the underlying test.

*SROC curve.* Due to this comparability problem for sensitivity and specificity, interest is usually focussed on the *summary receiver operating characteristic* (SROC) curve consisting of the pairs (1−*q*(*t*),*p*(*t*)) where *q*(*t*)= *P*(*T*\<*t*\|*D*=0) and *p*(*t*)=*P*(*T*≥*t*\|*D*=1) for a continuous test *T* with potential value *t*. For a given study *i*, *i*=1,⋯,*k*, with potentially unknown cut--off value *t*~*i*~, the pairs (1−*q*(*t*~*i*~),*p*(*t*~*i*~)) can be estimated by $\left( 1 - {\hat{q}}_{i},{\hat{p}}_{i} \right) = \left( 1 - x_{i}/n_{i},y_{i}/m_{i} \right)$ for *i*=1,...,*k*. The SROC curve accommodates the cut--off value problem. Different pairs could have quite different values of specificity and sensitivity, but still reflect identical diagnostic accuracy. The SROC diagram for the meta--analysis on BNP and heart failure is given in Figure [1](#F1){ref-type="fig"}.

![SROC diagram for BNP and heart failure: circles are the observed pairs of false positive rate and sensitivity, dashed curve is lowess smoother.](1471-2288-14-56-1){#F1}

Clearly, there is a wide range of values for specificity and sensitivity. Nevertheless, as Figure [1](#F1){ref-type="fig"} shows, the possibility that the pairs might stem from a common SROC curve (as given by the dashed curve in Figure [1](#F1){ref-type="fig"}) cannot be discarded. Since the SROC approach accommodates the cut-off value problem, it is commonly preferred to summary measures like the Youden index \[[@B10]\] or the diagnostic odds ratio \[[@B11]\]. In the following, we focus our analysis on the SROC curve.

*Background of SROC modelling.* SROC modelling has received considerable attention in the field and experienced several developments. An early model was suggested by Littenberg and Moses \[[@B12]\], \[[@B13]\] and has been used in practice frequently; Deeks \[[@B3]\] discusses its prominent role in modeling meta-analytic diagnostic study accuracy. Littenberg and Moses \[[@B13]\] suggest fitting *D*=*α*+*βS*, where $D = \log\textit{DOR} = \log\frac{p}{1 - p} - \log\frac{1 - q}{q}$ is the *log-diagnostic odds ratio* and $S = \log\frac{p}{1 - p} + \log\frac{1 - q}{q}$ is a measure for a potential threshold effect. After *α* and *β* have been estimated from the data, the SROC-curve (*p* vs. 1−*q*) is reconstructed from the estimated values of *α* and *β*. The parameter *α* is interpreted as the *summary log-DOR*, which is adjusted by means of *S* for potential *cut-off value effect*.

A two--level approach has been suggested by Rutter and Gatsonis \[[@B14]\], which is typically given in the following notational form (Walter and Macaskill \[[@B15]\]): let *Z*~*i*\ *j*~∼*Bi*(*n*~*i*\ *j*~,*π*~*i*\ *j*~), where *Z*~*i*\ *j*~ is the number of test-positives in study *i* for arm *j* (*j*=1 is diseased, *j*=2 is non-diseased), *n*~*i*\ *j*~ is the size of arm *j* in study *i* and *π*~*i*1~ is the sensitivity, *π*~*i*2~ is the false positive rate; the model is $\log\frac{\pi_{\textit{ij}}}{1 - \pi_{\textit{ij}}} = \left( \theta_{i} + \alpha_{i}\textit{DS}_{\textit{ij}} \right)\exp\left( - \beta\textit{DS}_{\textit{ij}} \right),$ where *θ*~*i*~ is an implicit threshold parameter for study *i*, *α*~*i*~ is the diagnostic accuracy parameter in study *i*, and *DS*~*i*\ *j*~ represents a binary variable for the disease status. The parameter *β* allows for an association between test accuracy and test threshold. When *β*=0, *α*~*i*~ is estimated by *D*~*i*~ and *θ*~*i*~ is estimated by *S*~*i*~/2, where *D*~*i*~ and *S*~*i*~ are as for the Littenberg--Moses model. Furthermore, to account for between-study variation, a random effect is assumed for $\theta_{i} \sim N\left( \Theta,\tau_{\theta}^{2} \right)$ and $\alpha_{i} \sim N\left( \Lambda,\tau_{\alpha}^{2} \right)$, with *θ*~*i*~ and *α*~*i*~ being independent. As an alternative, a bivariate normal random-effects meta--analysis has been suggested by van Houwelingen *et al.*\[[@B16]\]; see also Reitsma *et al.*\[[@B17]\] and Arends *et al.*\[[@B18]\]. Harbord *et al.*\[[@B19]\] show that these models are closely related.

*Paper overview.* In the following, we propose a specific model, called the Lehmann model, which we believe is very attractive for the analysis of SROC curves. The model involves study--specific sensitivities and specificities and a diagnostic accuracy parameter which connects the two. The Lehmann model achieves flexibility by allowing the diagnostic accuracy parameter to become a random effect. In this it is similar to the Rutter-Gatsonis model, but differs in that it retains univariate dimensionality in its outcome measure and, hence, allows a mixed model approach in a more conventional way. In section "The proportional hazards measure", the proportional hazards measure is motivated as a specific form of SROC curve modelling and is compared to other approaches. Section "A mixed model approach" introduces the specific mixed model in which the log proportional hazards measure forms the outcome measure, the study factor is a normally distributed random effect (to cope with unobserved heterogeneity), and other observed covariates (such as gold standard or diagnostic test variation) are considered as fixed effects in the mixed model. Section "Results" considers various applications including a meta-analysis of the Mini-Mental State Examination to diagnose dementia or mild cognitive impairment. It also provides SAS-code for a simple execution of the suggested approach. In section "Discussion", the choice of outcome is discussed and the difference between global and local diagnostic accuracy measures highlighted. This is particularly of interest if observed cut-off value variation occurs in the meta-analysis and needs to be assessed. Here a local criterion of diagnostic accuracy appears more appropriate. The paper ends with some brief conclusions and discussion in section "Conclusions".

Methods
=======

The proportional hazards measure
--------------------------------

Numerous summary measures for a pair of specificity and sensitivity have been suggested: we mention here the Youden index, *J*~*i*~=*p*~*i*~+*q*~*i*~−1 \[[@B10]\], and the squared Euclidean distance to the upper left corner in the SROC diagram, *E*~*i*~=(1−*p*~*i*~)^2^+(1−*q*~*i*~)^2^. \[A review of summary measures is given in Liu \[[@B20]\].\] Using an average over any of these measures might be problematic: not only might sensitivities and specificities be heterogeneous, this might also be true for the associated summary measures such as the Youden index or the Euclidean distance (as demonstrated by Figure [2](#F2){ref-type="fig"} using the data of the meta-analysis of BNP and heart failure).

![Index plots for sensitivity, specificity, Youden index, and Euclidean distance showing the wide variability of these measures for the data of the meta-analysis of BNP and heart failure.](1471-2288-14-56-2){#F2}

We suggest using the measure $\theta = \frac{\log p}{\log\left( 1 - q \right)}$, which relates the log-sensitivity to the log-false positive rate; we call it the *proportional hazards (PH)* measure. In Figure [3](#F3){ref-type="fig"} we see that this measure shows a reduced variability for the meta-analysis of BNP and heart failure, making it more suitable as an overall measure in the meta-analysis of diagnostic studies or diagnostic problems. While the measure appears to be like any other summary measure of the pair sensitivity and specificity, it has a specific SROC-modelling background and motivation. We have mentioned previously the cut-off value problem: observed heterogeneity might be induced by cut-off value variation which could lead to different sensitivities and specificities -- despite the accuracy of the diagnostic test itself not having changed -- and might also lead to an induced heterogeneity in the summary measure. Hence, it is unclear whether the observed heterogeneity is due to heterogeneity in the diagnostic accuracy (authentic heterogeneity) or whether it has occurred due to cut-off value variation (artificial heterogeneity). This second form of heterogeneity can also occur when the background population changes with the study.

![Index plots for the PH measures for the data of the meta-analysis of BNP and heart failure.](1471-2288-14-56-3){#F3}

One of the features of the SROC approach is that it incorporates the cut-off value variation in a natural way; hence a measure modelling an ROC curve is favorable. We suggest the PH measure based upon the Lehman family in the following way:

$$p = \left( 1 - q \right)^{\theta}.$$

This model was suggested by Le \[[@B21]\] for the ROC curve. It is an appropriate model since, for feasible *q*, (1−*q*)^*θ*^ is also feasible as long as *θ* is positive. Note that (1) is defined for all values of *p*∈\[0,1\] and *q*∈ \[ 0,1\] whereas $\theta = \frac{\log p}{\log\left( 1 - q \right)}$ is only defined for *p*∈(0,1) and *q*∈(0,1). Population values of sensitivity and specificity of 1 are rarely realistic, although observed values of 1 for sensitivity and specificity do occur in samples. This can be coped with by using an appropriate smoothing constant such as estimating specificity as (*n*~*i*~−1)/*n*~*i*~ when *x*~*i*~=*n*~*i*~ and sensitivity as (*m*~*i*~−1)/*m*~*i*~ if *y*~*i*~=*m*~*i*~.

In Figure [4](#F4){ref-type="fig"} we see a number of examples of the proportional hazards family. It becomes clear now why *θ* is called the proportional hazards measure. By taking logarithms on both sides of (1) we achieve

$$\theta = \log p\left( t \right)/\log\;\left\lbrack \; 1 - q\left( t \right) \right\rbrack,$$

![**Some examples of the proportional hazards model for various values of*θ*.**](1471-2288-14-56-4){#F4}

meaning if model (1) holds, the ratio of log-sensitivity to log-false positive rate is constant across the range of possible cut-off value choices *t*. Hence the name proportional hazards model, which was suggested in a paper by Le \[[@B21]\] and used again in Gönen and Heller \[[@B22]\]. The idea of representing an entire ROC curve in a *single* measure is illustrated in Figure [5](#F5){ref-type="fig"}. While sensitivity and specificity vary over the entire interval (0,1), the value of *θ* remains constant. Hence, log-sensitivity is *proportional* to the log-false positive rate. This assumption is similar to an assumption used for a model in survival analysis, where it is assumed that the hazard rate of interest is proportional to the baseline hazard rate; this might have motivated the choice of name used by Le \[[@B21]\] and Gönen and Heller \[[@B22]\] in this context.

![Proportional hazards model and associated PH measure.](1471-2288-14-56-5){#F5}

However, it is not our intention to make the assumption that an entire SROC curve can be represented by model (1); the explanations above are instead meant as a motivation that the PH-measure is not just another summary measure, but can be derived from a ROC modelling perspective. We envisage that each study, with associated pair of sensitivity and specificity, can be represented by a specific PH-model, as illustrated in Figure [6](#F6){ref-type="fig"}.

![**Meta-analysis of BNP and heart failure: each study is represented by its own PH model (**1**) -- illustrated for 3 studies.**](1471-2288-14-56-6){#F6}

We see indeed that each pair of sensitivity and specificity can be associated with its own ROC curve provided by

$$p = \left( 1 - q \right)^{{\hat{\theta}}_{i}}$$

where ${\hat{\theta}}_{i} = \log{\hat{p}}_{i}/\log\;\left\lbrack \; 1 - {\hat{q}}_{i} \right\rbrack$, so that the curve (3) passes exactly through the point $\left( 1 - {\hat{q}}_{i},{\hat{p}}_{i} \right)$.

*Comparison to other approaches.* It remains to be seen how appropriate the suggested proportional hazards model is and how it compares to other existing approaches. We emphasize that in our situation we have assumed that there is only *one* pair of sensitivity and false positive rate $\left( {\hat{p}}_{i},1 - {\hat{q}}_{i} \right)$ per study *i*. Situations where several pairs per study are observed (such as in Aertgeerts *et al.*\[[@B23]\]) are rare. Hence, on the log-scale for sensitivity and false-positive rate, we are not able to identify any straight line model *within a study* with *more than one* parameter, since this would require at least two pairs of sensitivity and specificity per study; see also Rücker and Schumacher \[[@B24],[@B25]\]. However, any one-parameter straight line model, such as the proposed proportional hazards model, is estimable within each study, although within-model diagnostics is limited since we are fitting the full within study model. Given that sample sizes within each diagnostic study are typically at least moderately large it seems reasonable to assume a bivariate normal distribution for $\log\hat{p}$ and $\log\left( 1 - \hat{q} \right)$ with means log*p* and log(1−*q*) as well as variances $\sigma_{p}^{2}$ and $\sigma_{q}^{2}$, respectively, and covariance *σ* with correlation *ρ*=*σ*/(*σ*~*p*~*σ*~*q*~). This is very similar to the assumptions in the approach taken by Reitsma *et al.*\[[@B17]\] (see also Harbord *et al.*\[[@B19]\]), with the difference that we are using the log-transformation whereas in Reitsma *et al.*\[[@B17]\] logit-transformations are applied. Then, it is a well-known result that the mean of the random variable $\log\hat{p}$ (having unconditional mean log*p*) conditional upon the value of the random variable $\log\left( 1 - \hat{q} \right)$ (having unconditional mean log(1−*q*)) is provided as

$$E\left( \log\hat{p} \middle| \log\left( 1 - \hat{q} \right) \right) = \log p + \rho\frac{\sigma_{p}}{\sigma_{q}}\left\lbrack \;\log\left( 1 - \hat{q} \right) - \log\left( 1 - q \right) \right\rbrack,$$

which can be written as $\alpha + \theta\left\lbrack \;\log\left( 1 - \hat{q} \right) \right\rbrack$ where *α*= log(*p*)−*θ* log(1−*q*) and $\theta = \rho\frac{\sigma_{p}}{\sigma_{q}}$. This is an *important* result since it means that, in the log-space, sensitivity and false--positive rate are linearly related. Furthermore, if *α* is zero, the proportional hazards model arises.

The question then arises why not work with a straight line model

$$\log p_{|\log(1 - q)} = \alpha + \theta\log\left( 1 - q \right).$$

The answer is that such a model is *not identifiable* since we have only one pair of sensitivity and specificity observed in each study and it is not possible to uniquely determine a straight line by just one pair of observations since there are infinitely many possible lines passing through a given point in the log*p* -- log(1−*q*) space. However, the proportional hazards model as a slope-only model *is* identifiable and it is more plausible than other identifiable models such as the intercept--only model. Clearly, a logistic-transformation would be more consistent with the existing literature \[[@B14],[@B15]\] than the log-transformation. However, both models would give a perfect fit (within each study) since there are no degrees of freedom left for testing the model fit. The situation changes when there are repeated observations of sensitivity and specificity *per study* available. However, these meta-analyses with repeated observations of sensitivity and specificity according to cut-off value variation are extremely rare.

A mixed model approach
----------------------

With the motivation of the previous sections in mind, we assume that *k* diagnostic studies are available with diagnostic accuracies ${\hat{\theta}}_{1},\cdots\;,{\hat{\theta}}_{k}$ where

$${\hat{\theta}}_{i} = \frac{\log{\hat{p}}_{i}}{\log\left( 1 - {\hat{q}}_{i} \right)}.$$

We assume the following linear mixed model for $\log{\hat{\theta}}_{i}$:

$$\log{\hat{\theta}}_{i} = \mathbf{\beta^{T}x}_{i} + \delta_{i} + \varepsilon_{i}$$

where **x**~*i*~ is a known covariate vector in study *i*, *δ*~*i*~ is a normally distributed random effect *δ*~*i*~∼*N*(0,*τ*^2^) with *τ*^2^ being an unknown variance parameter, and $\varepsilon_{i} \sim N\left( 0,\sigma_{i}^{2} \right)$ is a normally distributed random error with variance $\sigma_{i}^{2}$ known from the *i*−th study.

There are several noteworthy points about the mixed model (7). The response is measured on the log-scale, where the transformation improves the normal approximation and also brings the diagnostic accuracy into a well-known link function family: the complementary log-log function. The difference of the probability for a positive test in the groups with and without the condition is measured on the complementary log-log scale. The fixed effect part involves a covariate vector **x** which could contain information on study level such as gold standard variation, diagnostic test variation, or sample size information. It should be noted that there are two variance components, *τ*^2^ and $\sigma_{i}^{2}$. It is important to have information on the second variance component. If the second component is unknown, even under the assumption of homogeneity $\sigma_{1}^{2} = \cdots = \sigma_{k}^{2}$, the variance component model would *not* be identifiable. Hence, we need to devote some effort to derive expressions for the within study variances; this can be accomplished using the *δ*−method as discussed in the next section.

*Within study variance.* Let us consider (ignoring the study index *i* for the sake of simplicity)

$$\log\hat{\theta} = \log\left( - \log\hat{p} \right) - \log\;\left\lbrack \; - \log\left( 1 - \hat{q} \right) \right\rbrack$$

and apply the *δ*−method. Recall that the variance *VarT*(*X*) of a transformed random variable *T*(*X*) can be approximated as \[ *T*^′^(*E*(*X*))\]^2^*Var*(*X*) assuming that the variance *Var*(*X*) of *X* is known. Applying this *δ*−method twice gives

$$\textit{Var}\log\left( - \log\hat{p} \right) \approx \frac{\hat{p}\left( 1 - \hat{p} \right)/m}{{\hat{p}}^{2}\left( \log\hat{p} \right)^{2}}$$

and

$$\textit{Var}\log\left( - \log\left( 1 - \hat{q} \right) \right) \approx \frac{\hat{q}\left( 1 - \hat{q} \right)/n}{\left( 1 - \hat{q} \right)^{2}\left( \log\left( 1 - \hat{q} \right) \right)^{2}}$$

so that the within study variance for the *i*-th study is provided as

$$\sigma_{i}^{2} = \frac{m_{i} - y_{i}}{m_{i}y_{i}\left( \log y_{i}/m_{i} \right)^{2}} + \frac{x_{i}}{n_{i}\left( n_{i} - x_{i} \right)\left( \log\left( 1 - x_{i}/n_{i} \right) \right)^{2}}.$$

We acknowledge that the above are estimates of the variances of the diagnostic accuracy estimates, but are used as if they were the true variances.

*Some important cases.* If there are no further covariates, *two* important models are easily identified as special cases of (7). One is the *fixed* effects model

$$\log{\hat{\theta}}_{i} = \beta_{0} + \varepsilon_{i}$$

and the other is the *random* effects model

$$\log{\hat{\theta}}_{i} = \beta_{0} + \delta_{i} + \varepsilon_{i}$$

which have gained some popularity in the meta-analytic literature.

Results
=======

Case study on MMSE and dementia
-------------------------------

We illustrate the approach with an example and revisit a meta--analysis by Mitchell \[[@B26]\] on the diagnostic accuracy of the mini-mental state examination (MMSE) as a diagnostic test for the detection of dementia and, more recently, mild cognitive impairment (MCI). In this meta--analysis 38 studies were included and the entire data are reproduced in Table [2](#T2){ref-type="table"}. We are interested in the question: is there a difference in diagnostic accuracy of the MMSE in the detection of dementia and MCI, as Figure [7](#F7){ref-type="fig"} suggests.

###### 

Meta-analysis of the diagnostic accuracy of the mini-mental state examination (MMSE) and dementia or mild cognitive impairment (MCI) as reference standard; TP = true positives, FN = false negatives, FP = false positives, TN = true negatives

  **Study**    **Condition**   **TP**   **FN**   **FP**   **TN**
  ----------- --------------- -------- -------- -------- --------
  1              Dementia        65       3       240      870
  2              Dementia       117       12       10      110
  3              Dementia        48       19       63      989
  4              Dementia       134       8        28      152
  5              Dementia        24       5        44      292
  6              Dementia        67       15       48      153
  7              Dementia        64       17       1        71
  8              Dementia       281       64       20      286
  9              Dementia        13       1        44      286
  10             Dementia       262       20       29      177
  11             Dementia       143       18       29      123
  12             Dementia       183       33       33       51
  13             Dementia        22       1       152      140
  14             Dementia       112       1       590      2091
  15             Dementia       152       81      126      1009
  16             Dementia        29       26       26      236
  17             Dementia        31       6        3       247
  18             Dementia        10       3        12      333
  19             Dementia       707       88      1438    10447
  20             Dementia       181      108       17      184
  21             Dementia        59       29       23       74
  22             Dementia        74       23       16      143
  23             Dementia        27       12       26      209
  24             Dementia        40       6        75      528
  25             Dementia       317       52      173      578
  26             Dementia       387      116       16       54
  27             Dementia       118       65       1        44
  28             Dementia        44       7        34      396
  29             Dementia       123       46       98      309
  30             Dementia        25       43       3       171
  31             Dementia        73       32       2       225
  32             Dementia        37       45       1       440
  33             Dementia        78       34       45      376
  34                MCI          72       12       53      214
  35                MCI         106       23      410      379
  36                MCI          37       36       22      118
  37                MCI          67       30       22       75
  38                MCI          17       77       1        90

![SROC diagram for the meta--analysis of MMSE and dementia or MCI as reference standard.](1471-2288-14-56-7){#F7}

We use `proc mixed` from the SAS software, version 9.2 for Windows \[[@B27]\], for the analysis (see also Table [3](#T3){ref-type="table"}). The values of the dependent variable $\log{\hat{\theta}}_{i}$ are easily constructed from Table [2](#T2){ref-type="table"}. We are interested to see if there are differences in accuracy for diagnosing MCI compared to diagnosing dementia. Hence we have constructed a covariate `condition` which takes the value 1 if the study concerns MCI as condition and 0 if the study is on dementia. Since we have fixed within-study variances, we need to tell `proc mixed` to incorporate this appropriately; this can be accomplished by using a weight, $w_{i} = 1/\sigma_{i}^{2}$. The `random` option induces a random effect (here `study`) with associated variance component *τ*^2^, which is estimated. However, SAS `proc mixed` will automatically fit a within-study variance component (on top of the provided variances). To circumvent this mechanism, the option `parms (1) (1) /hold=2` is used where the term `hold=2` fixes the second variance component, corresponding to the within-study variance multiplier, to one. Note that the random effect modelling between-study variation is described by a free variance parameter, *τ*^2^. For this a starting value needs to be given: we have *τ*^2^=1, although other choices are possible, e.g. *τ*^2^=0, corresponding to the case of no heterogeneity between studies.

###### 

**SAS proc**mixed**adapted for meta--analysis of diagnostic accuracy study data**

  **SAS statement**                                                        **Explanation**
  ------------------------------------------- -------------------------------------------------------------------------
  `proc mixed data=MMSE method=ml covtest;`       procedure `mixed` of SAS, `data` contains the data file, `method`
                                                                        specifies estimation
  `class study condition;`                                     defines the categorical variables used
  `model logtheta = condition/s;`                        defines the model: LHS outcome, RHS covariates used
  `weight w;`                                                  `w` contains inverse variance as weight
  `random study(condition);`                                    factor `study` nested in `condition`
  `parms (1) (1)/hold=2;`                      specifies starting values, hold=2 fixes the residual variance component
  `run;`                                                                executes the program

The results of the analysis are provided in Table [4](#T4){ref-type="table"}. It can be seen that there is a significant effect of condition (dementia/MCI) on the diagnostic accuracy, with diagnostic accuracy being significantly higher in studies with patients having dementia in comparison to the diagnostic accuracy in studies with patients having mild cognitive impairment. Nevertheless, not all heterogeneity is explained by this covariate as the random effect (study effect) still remains significant, as the bottom part of Table [4](#T4){ref-type="table"} shows.

###### 

Analysis of effects for the meta-analysis of the diagnostic accuracy of the mini-mental state examination (MMSE) and dementia or mild cognitive impairment (MCI) as reference standard

  **Effect**        **Parameter**   **SE**   **Z-value**
  ---------------- --------------- -------- -------------
  fixed                                            
  Intercept            -2.2878      0.1208     -18.94
  condition            0.8605       0.3187      2.70
  random                                           
  *τ*^2^ (study)       0.3078       0.1049      2.90

The inference is based here on a procedure called the Wald test. The estimated parameter value is divided by its estimated standard error, and the result is given in column four in Table [4](#T4){ref-type="table"}. The likelihood ratio test may be considered as an alternative. It is defined as two times the difference of the log-likelihood including the effect of interest and the log-likelihood not including the effect of interest. For the effect of condition in Table [4](#T4){ref-type="table"}, we find a value of 6.8 for the likelihood-ratio test. The Wald test is asymptotically standard normal under the null-hypothesis of absence of effect, whereas the likelihood ratio test statistic is asymptotically chi-squared distributed with degrees of freedom equal to the number of parameters associated with the effect considered (in this case one). It is well-known that the likelihood ratio test is more powerful. Here, both tests provide similar p-values, with 0.0091 for the likelihood ratio test and 0.0069 for the Wald test; this confirms the significance of the effect (dementia/MCI) on the diagnostic accuracy.

It is trivial to construct the associated SROC curves from Table [4](#T4){ref-type="table"}. We find

$$\begin{array}{lll}
{\text{for\ dementia:}\mspace{500mu} p} & {= \left( 1 - q \right)^{\exp( - 2.2878)},\qquad} & \qquad \\
{\mspace{47mu}\text{for\ MCI:}p} & {= \left( 1 - q \right)^{\exp( - 2.2878 + 0.8605)}.\qquad} & \qquad \\
\end{array}$$

Note that the likelihood ratio test as well as the Wald test need modification in situations where the null hypothesis is part of the boundary of the alternative such as when testing H ~0~:*τ*^2^=0. In this case, the asymptotic null distribution of the likelihood ratio test statistic is no longer *χ*^2^ with 1 df but rather a mixture of a two-mass distribution giving equal weights 0.5 to the one-point mass distribution at 0 and a *χ*^2^ with 1 df \[[@B28]\]. Practically, this means that standard 2-sided p-values have to be divided by 2.

Case study on MOOD and depressive disorders
-------------------------------------------

The MOOD module of the Patient Health Questionnaire (PHQ-9) has been developed to screen and to diagnose patients in primary care with depressive disorders. The instrument consists of 9 questions, each scored from 0 to 3 points with a total score ranging from 0 to 27. In a meta--analysis of the diagnostic accuracy of MOOD, Wittkampf *et al.*\[[@B29]\] included 12 studies. These studies used either a cut-off of 10 (referred to here as "summary score") or a more complex evaluation algorithm ("algorithm"). The complete data are listed in Table [5](#T5){ref-type="table"} and the associated SROC diagram is given in Figure [8](#F8){ref-type="fig"}. The impression from the graph is that the cut-off of 10 used by the summary score has a higher diagnostic accuracy than the alternative.

###### 

Meta-Analysis of the diagnostic accuracy of the MOOD module and depression in patients in primary care as reference standard; TP = true positives, FN = false negatives, FP = false positives, TN = true negatives

  **Study**    **Cut-off**   **TP**   **FN**   **FP**   **TN**
  ----------- ------------- -------- -------- -------- --------
  1             algorithm      65       26      104      1192
  2             algorithm      70       13       74      846
  3             sum score      62       10       27      429
  4             sum score      36       5        65      474
  5             sum score      55       11       43      392
  6             algorithm      6        8        12      144
  7             sum score     121      103       80      720
  8             algorithm      11       5        5        76
  9             algorithm      6        5        0        3
  10            algorithm      85       31       9       460
  11            sum score      15       1        4        42
  12            sum score      96       10       23      187

![SROC diagram for the meta--analysis of MOOD and depression in patients in primary care.](1471-2288-14-56-8){#F8}

The presence or absence of a cut-off value effect is now more formally investigated using a covariate `cut-off`, which is zero when the summary score with a cut-off value of 10 is used and one otherwise. The results are presented in Table [6](#T6){ref-type="table"}. It can be seen that the covariate `cut-off` level "summary score" is associated with a higher diagnostic accuracy, although, as seen from the Wald statistics provided in column four of Table [6](#T6){ref-type="table"}, the effect is not significant. We see a significant random effect (study; adjusted p-value 0.0274; see comment at the end of section "Case study on MMSE and dementia"), which indicates that the random study effect is needed in the analysis. It is not really surprising that the covariate `cut-off` is not significant, since the concept of the SROC is designed to accommodate the cut-off value variation. We will take up this point in the next section.

###### 

Analysis of the cut-off effect for the meta-analysis of the MOOD module and depression in patients in primary care

  **Effect**        **Parameter**   **SE**   **Z-value**
  ---------------- --------------- -------- -------------
  fixed                                            
  Intercept            -2.5332      0.2817      -8.99
  cut-off              0.4804       0.3966      1.21
  random                                           
  *τ*^2^ (study)       0.3239       0.1690      1.92

Discussion
==========

Global versus local criteria
----------------------------

We have focussed on the PH measure so far, as it provides an appropriate measure for comparing SROC curves *globally*, in the sense that cut-off value variation will not necessarily effect the estimate of the SROC curve. The situation is illustrated in Figure [9](#F9){ref-type="fig"}.

![Different cut-off values with associated sensitivities and specificities on the same SROC curve with different Euclidean distances; the point on the circle has shortest Euclidean distance to the upper left vertex of the SROC diagram as indicated by the circle.](1471-2288-14-56-9){#F9}

Evidently, different cut-off values are associated with the same value of log*θ*, hence, the PH measure log*θ* is not the best measure to discriminate different cut-off values. This is not surprising, since the SROC curve is a concept designed for assessing the diagnostic accuracy of a diagnostic test globally, in the sense that it adjusts for different cut-off values. Hence, a measure that assesses local performance of the diagnostic is needed. Assuming that every cut-off value used in the meta--analysis is clinically meaningful, we suggest use of the (squared) Euclidean distance to the upper left corner (0,1) of the ROC diagram as a more meaningful measure to compare cut-off values:

$$Ê_{i} = \left( 1 - {\hat{p}}_{i} \right)^{2} + \left( 1 - {\hat{q}}_{i} \right)^{2},$$

where ${\hat{p}}_{i} = y_{i}/m_{i}$ and ${\hat{q}}_{i} = x_{i}/n_{i}$. Each point in the SROC diagram has a unique circle with center (0,1) that passes through this point. In Figure [9](#F9){ref-type="fig"}, one such circle is illustrated which also has the smallest Euclidean distance among the three available points (since it has smallest radius among the three possible points with associated circles). In the following, we will consider the criterion (14) as an alternative criterion to choose the cut-off value.

Since we have changed the criterion, we need to determine the associated within-study variances. This can be accomplished easily, using the *δ*-method once more, to obtain

$$\textit{Var}\left( Ê \right) \approx 4\left( 1 - \hat{p} \right)^{2}\hat{p}\left( 1 - \hat{p} \right)/m + 4\left( 1 - \hat{q} \right)^{2}\hat{q}\left( 1 - \hat{q} \right)/n,$$

where we have ignored study indexes for the the sake of simplicity. Using this criterion, we see in Figure [9](#F9){ref-type="fig"} that cut-off values can vary considerably in their diagnostic accuracy, despite having identical diagnostic accuracy at a global level. We re-analyze the meta--analysis of MOOD and depression with respect to the (squared) Euclidean distance and provide the results in Table [7](#T7){ref-type="table"}.

###### 

Analysis of the cut-off effect for the meta-analysis of the MOOD module and depression in patients in primary care

  **Criterion**         **Effect**   **Parameter**   **SE**   **Z-value**
  -------------------- ------------ --------------- -------- -------------
  PH measure             cut-off        0.4804       0.3966      1.21
  Euclidean distance     cut-off        0.0563       0.0430      1.31

Evidently, both criteria lead to the same conclusion, namely that using the summary score with a cut-off value of 10 leads to the higher diagnostic accuracy (although the effect is not significant). It might also be worthwhile looking at the results of the likelihood ratio test: for the PH-measure as the outcome variable, the likelihood ratio test provides a value of 1.5; for the Euclidean distance, the value of the likelihood ratio test is 1.7, confirming the non-significance of the effect. Nevertheless, the analysis shows that the cut-off value of 10 provides the higher diagnsotic accuracy.

Meta--analysis of magnetic resonance spectroscopy and prostate cancer
---------------------------------------------------------------------

This case study provides an example where the use of a global or local criterion leads to a different conclusion. Magnetic resonance spectroscopy has the ability to discriminate between prostate cancer and benign prostatic hyperplasia, based on reduced citrate and elevated choline in the cancerous region. The diagnostic test works on a voxel of signal intensity ratios of (choline+creatine)/citrate. Two cut-off points are in use: \<0.75 and \<0.86. The results collected in a meta--analysis by Wang *et al.*\[[@B30]\] include 12 studies, as presented in Table [8](#T8){ref-type="table"}; the associated SROC diagram is presented in Figure [10](#F10){ref-type="fig"}. From the graph, there is no obvious choice for the "best" cut-off value.

###### 

Meta-analysis of the magnetic resonance spectroscopy and prostate cancer; TP = true positives, FN = false negatives, FP = false positives, TN = true negatives

  **Study**    **Cut-off**   **TP**   **FN**   **FP**   **TN**
  ----------- ------------- -------- -------- -------- --------
  1               0.75        122       30       35       55
  2               0.75         73       8        80      219
  3               0.75         75       6        92      207
  4               0.75        123       39       38       50
  5               0.75        134       21       40       39
  6               0.75         12       12       7        75
  7               0.86         81       71       24       59
  8               0.86         56       25       32      267
  9               0.86         52       29       20       59
  10              0.86         98       57       20       59
  11              0.86         6        9        15      266
  12              0.86         44       8        32      264

![SROC diagram for the meta-analysis of the magnetic resonance spectroscopy and prostate cancer.](1471-2288-14-56-10){#F10}

The fixed effects parts of the mixed model analysis, using the global PH measure and the local Euclidean measure as criteria, are presented in Table [9](#T9){ref-type="table"}. It is interesting to note that the focus of the analysis, global or local, is an important part of the analysis. Globally, the better diagnostic accuracy is given by the cut-off value of 0.75, whereas better local performance is achieved with a cut-off value of 0.86, although neither analysis is significant.

###### 

Analysis of the cut-off effect for the meta-analysis of the magnetic resonance spectroscopy and prostate cancer

  **Criterion**         **Effect (reference)**   **Parameter**   **SE**   **Z-value**
  -------------------- ------------------------ --------------- -------- -------------
  PH measure               cut-off (\<0.75)         0.2049       0.3516      0.58
  Euclidean distance       cut-off (\<0.75)         -0.0212      0.0573      -0.37

PH measure and positive likelihood ratio
----------------------------------------

Another frequently used diagnostic measure is the positive likelihood ratio, defined as the ratio of sensitivity to false positive rate *P*(*T*=1\|*D*=1)/*P*(*T*=1\|*D*=0) or *p*/(1−*q*). It is different to the PH measure in that the ratio is taken on the log-scale: *θ*= log*p*/ log(1−*q*). Furthermore, if re-expressed as models, the positive-likelihood ratio corresponds to *p*=*θ*^′^(1−*q*), a straight line with no intercept, whereas the the PH measure corresponds to *p*=(1−*q*)^*θ*^, a straight line on the log-scale with no intercept. The positive likelihood ratio is a natural measure since it transfers the concept of relative risk (risk of a positive test in the diseased group to the risk of a positive test in the non-diseased group) to the diagnostic setting. However, it is less suitable as an (S)ROC model since it does not provide a function which connects the lower left vertex with the upper right vertex in the ROC diagram (which, in contrast, the PH-model does provide).

Conclusions
===========

The approach presented here is attractive since it is based on a simple measure of diagnostic accuracy per study, namely the ratio of log-sensitivity to log-false-positive rate. It also embeds the diagnostic meta-analysis problem into the well-known and much used mixed model setting. In particular, the analysis of effects of observed covariates on the diagnostic accuracy can easily be incorporated.

Controversies in the meta--analysis of diagnostic studies usually focus on comparability of studies. Study types might be case--control, cohort, cross--sectional or other. Studies might differ in the gold standard, severity of disease, or in the application of the diagnostic test. Patient populations might differ across studies, as might the cut-off value (defining positivity of the diagnostic test). All these different aspects, if observed, can be easily incorporated and analyzed as fixed effects in the special mixed model suggested here.

The occurrence of heterogeneity in the meta-analysis of diagnostic studies is more the rule than the exception; it is thus important to quantify the heterogeneity across studies due to the different sources. The approach provided here offers a more detailed investigation of heterogeneity according to the various observed sources and a residual heterogeneity (measured by *τ*^2^). This might allow us to construct a measure of relative residual heterogeneity, which might help to assess how trustworthy the results of a given meta-analysis may be. This will be investigated in future research.

In a recent study on the meta-analytical evaluation of coronary CT angiography studies, Schuetz *et al.*\[[@B31]\] investigated the problem of non-evaluable results that occur in the individual studies. They conclude that diagnostic accuracy measures change considerably depending on how non-evaluable results are treated. In fact, they conclude that

parameters for diagnostic performance significantly decrease if non-evaluable results are included by a 3×2 table for analysis (intention to diagnose approach).

Twenty-six studies were included in their meta-analysis with a wide range of non-evaluable results from 0 to 43. Using the approach suggested here, it would be very easy to analyze the effect of non-evaluable results on the diagnostic accuracy by including the amount of non-evaluable results per study as a fixed effect in the proposed mixed model.
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